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Induced Hypertensive Therapy in an Acute Ischemic Stroke 
Patient with Early Neurological Deterioration
Hye-Jin Kim, M.D., Dong-Wha Kang, M.D., Ph.D.
Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine
Poststroke hypotension may be related to early neurological deterioration and infarct progression by decrease of 
cerebral perfusion, particularly in patients with ischemic penumbra. However, optimal management guideline of blood 
pressure in the setting of acute stroke is absent, and remains a matter of debate. We report here a patient who 
had early neurological deterioration accompanied by systemic hypotension. Phenylephrine-induced hypertensive 
therapy by imaging-based decision making successfully restored neurologic dysfunction in this patient. 
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A spontaneous increase in blood pressure (BP) is 
common in patients with acute ischemic stroke. The 
cause of this elevation has been attributed to auto-
nomic effects of stroke, stress of hospitalization, and 
the teleological need for the brain and ischemic 
penumbra to increase cerebral blood flow. Blood 
pressure tends to decline in the first few days to 
weeks after stroke onset, even without pharmacological 
intervention. 
The importance of BP management after stroke for 
secondary prevention has been well established. Unlike 
chronic stroke, however, BP reduction in acute stroke 
phase may lead to different and untoward effects. 
Vemmos et al. confirmed that poor outcome was 
seen in patients with either very high or very low 
initial BP, consistent with a ‘U-shaped’ curve.
1  There-
fore, the optimal management of BP in the setting of 
acute stroke is uncertain, and remains a matter of 
debate and demands further investigation. 
The early perfusion- (PWI) and diffusion-weighted 
magnetic resonance imaging (DWI) have been proposed 
as a useful method to evaluate ischemic penumbra. 
In patients with perfusion-diffusion mismatch, poststroke 
hypotension may cause early neurological deterioration 
and infarct progression by decrease of cerebral perfusion. 
The recanalization of occluded vessels using thrombolytic 
therapy or interventional procedures has been usually 
considered. Alternatively, restoration of neurologic 
dysfunction may be accomplished by way of BP 
elevation (‘induced hypertension’) to increase cerebral 
blood flow to threatened areas, particularly in whom 
thrombolytic or interventional therapy is not indicated. 
Here, we describe a patient with perfusion-diffusion 
mismatch who had early neurologic deterioration 
accompanied by systemic hypotension. The neurological 
deterioration was completely resolved following induced 
hypertensive therapy. Journal of Clinical Neurology: Vol. 3, No. 4, 2007
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Figure 1. A 68-year-old man presented with mild aphasia, dysarthria and right arm weakness (NIHSS score = 4). Initial MRI 
shows acute ischemic lesions in the left middle cerebral artery (MCA) territory on diffusion weighted image (DWI) (A) with a 
larger perfusion defect on mean transit time map (B) not accompanied with clot or hemorrhage on gradient echo image (GRE) 
(C) and severe stenosis or occlusion of left proximal MCA on MR angiography (D). At hospital day 4, global aphasia, left gaze 
preference, right facial palsy, and right hemiparesis grade IV developed (NIHSS score = 12). DWI shows some additional 
scattered ischemic lesions in the left MCA territory (E). Intra-arterial thrombolysis was performed, and urokinase of 100,000 unit 
was applied. Final angiogram shows that left MCA is still occluded (F).
CASE REPORT
A 68-year-old man suddenly developed mild aphasia, 
dysarthria and right arm weakness. These symptoms 
occurred after excessive sweating during hiking in 
the mountains on day time. The patient arrived at 
emergency room 16 hours 30 minutes after symptom 
detection. The symptoms had an improving course at 
that time. He had hypertension and chronic renal 
failure, and had been treated with medications during 
the past 20 years. In addition, he had coronary heart 
disease and underwent coronary artery bypass graft 
surgery 1 year ago.
On the initial neurological examination, he was 
alert and had mild motor-dominant aphasia. Mild 
dysarthria without facial palsy was noted. Motor and 
sensory function tests were normal. Deep tendon 
reflexes and cerebellar function tests were also 
normal. Initial National Institutes of Health Stroke 
Scale (NIHSS) score was 4. The result of his chest 
x-ray and electrocardiogram showed normal configu-
ration. Initial BP was 128/73 mmHg. A brain magnetic 
resonance imaging (MRI) scan taken 17 hours after 
the onset, DWI showed acute infarct in the left 
middle cerebral artery (MCA) territory with a large Kim HJ, et al. Induced Hypertensive Therapy in Early Neurological Deterioration
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Figure 2. Temporal relationship between blood pressure and neurological dysfunction.
perfusion defect. A brain magnetic resonance angio-
gram (MRA) showed severe stenosis or occlusion in 
left proximal MCA (Fig. 1). Transthoracic echo-
cardiogram revealed normal cardiac chamber size, 
normal ejection fraction (66%) and mid-posterior 
wall thinning with akinesia in the left ventricle. 
Antiplatelet agents with aspirin and cilostazol and 
volume replacement with normal saline were admi-
nistered. 
At hospital day 4, neurological deterioration occurred 
to him. He had drowsy mental status, severe global 
aphasia, gaze preference to the left, right facial palsy, 
and right side hemiparesis (Medical Research Council 
grade IV). NIHSS score was 12. Blood pressure was 
87/52 mmHg at that time. The cause of BP drop was 
not clear. The blood tests including cardiac enzyme 
(creatinine kinase MB fraction, myoglobin, troponin-I) 
and electrocardiogram were unremarkable, but chest 
x-ray revealed mild pulmonary congestion. Despite 
severe clinical deterioration, the follow-up DWI 
showed some new scattered lesions in the left MCA 
territory, but did not show significant lesion growth 
compared with initial DWI. These findings suggested 
that the mechanism responsible for the neurological 
deterioration might be prolonged hemodynamic com-
promise rather than artery-to-artery embolism. Then 
catheter angiography was performed to consider intra- 
arterial recanalization therapy such as thrombolysis 
or stenting. 100,000 unit of urokinase was applied 
intra-arterially without any effect. Final angiogram 
showed that left M1 was still occluded. Then, BP 
elevation was tried by administration of normal 
saline 100 mL/hr and volume expander, hydroxyethyl 
starch 40 mL/hr for the increase of collateral circu-
lation. Follow-up BP was elevated to 100/55 mmHg, 
and then 120/70 mmHg 4 hours after neurological 
deterioration. However, his neurological deficits persisted 
throughout the treatment with intensive volume expander. 
Then, phenylephrine (60 μg/min) was administered. 
His systolic (SBP) and diastolic blood pressure 
(DBP) elevated more than 150 and 80 mmHg. While 
the systemic BP increased rapidly 1 hour after the 
administration of phenylephrine, the neurological 
deficits improved slowly, though steadily, over the 
following 24 hours. His neurological symptoms were 
fully recovered 36 hours later. We tapered out the 
pressor drugs, because his BP was maintained without 
further medication. The figure 2 shows the temporal 
relationship between BP and neurological symptoms. 
He had no adverse events related to pressor drugs. 
Antihypertensive medication was administered to the 
patient 7 days later, with his SBP being maintained 
between 140 and 150 mmHg. He has not developed 
recurrent neurological symptoms for the following 1 
year period.Journal of Clinical Neurology: Vol. 3, No. 4, 2007
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DISCUSSION
Poststroke hypotension is not rare phenomenon. 
According to previous reports, it could have been 
associated with neurological deterioration and poor 
outcome. In a retrospectively analysis of 17,398 
patients in the International Stroke Trial (IST),
2 18% 
of patients had SBP <140 mmHg, early (2-week) 
death increased by 17.9% for every 10 mmHg SBP 
below 150 mmHg.
3 As potential causes of poststroke 
hypotension, previous studies
4-6 suggested the poor 
left ventricular function and low cardiac output from 
heart disease (e.g., congestive heart failure, coronary 
heart disease, arrhythmia), the use of aggressive anti-
hypertensive medication, dehydration (e.g., diarrhea, 
poor oral intake), and septic condition due to hidden 
infection. In our patient, the chest x-ray showed mild 
pulmonary congestion at the time of neurological 
deterioration. Consequently, this finding supported 
that patient’s hypotensive episode may be associated 
with pre-existing heart disease.
In patients with perfusion-diffusion mismatch, post-
stroke hypotension may cause early neurological deterio-
ration and infarct progression by decrease of collateral 
blood flow.
7 Besides coronary heart disease, our 
patient had perfusion-diffusion mismatch accompanied 
with intracranial large artery disease, which suggest 
that this patient was particularly vulnerable to hemo-
dynamic compromise and had a high risk of early 
neurological deterioration. Despite clinical deterioration, 
follow-up DWI did not show additional significant 
infarcts. Therefore, we presumed that the main 
mechanism of neurological deterioration in this 
patient was hypoperfusion. 
Although pressor-induced hypertensive therapy is 
a standard treatment for cerebral ischemia in patients 
with vasospasm after subarachnoid hemorrhage, there 
are few experimental or human data to support this 
practice following acute ischemic stroke. In the ischemic 
penumbra as an area of brain surrounding of infarcted 
tissues, reversible electrical failrue was present, but 
irreversible cell death had not yet occurred. Increasing 
systemic BP in patients with low systemic BP could 
rescue the ischemic penumbra from cerebral infarct 
by increasing intraluminal hydrostatic pressure, opening 
collateral channels and improving cerebral blood 
flow and perfusion to penumbral ischemic tissues.
8 
We used phenylephrine as a pressor therapy. Pheny-
lephrine (a selective α1–agonist) increases BP by 
peripheral vasoconstriction, without substantial direct 
cerebral vasoconstriction, due to a low density of α1–
receptors in cerebral vessels.
9 It is less likely to 
cause of tachyarrhythmias, having negligible β–ago-
nist actionand increasing myocardial oxygen demand 
compared to other pressor agents. Hillis et al
10  found 
significant improvement of NIHSS, cognitive score 
and volume of hypoperfused tissue on PWI, in the 
phenylephrine-treated group with no adverse events 
such as cardiac ischemia or hemorrhagic conversion 
of infarct. We could not demonstrate elevated cerebral 
perfusion followed by induced hypertensive therapy 
in this case, because follow-up PWI was not performed. 
Current guidelines about the management of post-
stroke hypotension provide no objective clarification 
as to the appropriate management, which is a 
reflection of the paucity of evidence in this field. It 
is difficult to select patients who could benefit from 
pressor therapy and to define an absolute BP level at 
which pressor therapy should be considered. The 
most suitable candidate and therapeutic BP window 
for benefit is uncertain. In this patient, the elevation 
of systemic BP after the intra-arterial thrombolytic 
therapy might increase the risk of hemorrhage. However, 
we considered that benefit of reperfusion by induced 
hypertensive therapy might be higher than the risk of 
hemorrhage, because our patient received relatively 
small dose of urokinase (100,000 units) intra-arterially. 
Moreover, we tried to maintain the systolic BP no 
more than 160 mmHg. Large, well-designed trials are 
needed to clarify the management of arterial hypotension 
after acute stroke. Currently, a trial testing the utility 
of phenylephrine as a pressor therapy in the setting 
of stroke (Controlling Hypertension and Hypotension 
Immediately Post-Stroke [CHHIPS]) is ongoing.
11 
Before strong evidence is available, patients with 
significant SBP fall (e.g., > 20 mmHg) and neurological 
deterioration, particularly accompanied with pre-existing Kim HJ, et al. Induced Hypertensive Therapy in Early Neurological Deterioration
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large artery disease or cardiac dysfunction, may be 
considered as a therapeutic target. We regard that 
our patient fit well into this category. The reason for 
the lag between BP elevation induced by phenylephrine 
and subsequent neurologic improvement is not clear. 
Although SBP was elevated to more than 150 mmHg 
after phenylephrine infusion, the BP might be still 
below optimal range. Another possible explanation is 
that the time lag exists from BP elevation to increase 
of collateral circulation and cerebral perfusion and 
ultimately to clinical improvement. Stunned brain 
syndrome, which can sometimes be observed after 
reperfusion therapy,
12 is less likely, because the BP 
after phenylephrine infusion was not higher than BP 
before neurological deterioration. 
Although we report a single case, this report rein-
forces the utility of DWI and PWI in identifying the 
mechanism of early neurological deterioration and in 
guiding the clinical decision for administration of the 
most appropriate management. Active induced hyper-
tensive therapy can be considered, when a viable 
ischemic penumbra exists on early MRI and a neuro-
logical deterioration is accompanied by hemodynamic 
compromise.
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